FDA asks for risk plan info on diabetes drug

Courtesy Newsvine - business  Mon, 03/15/2010 - 04:56

Amylin Pharmaceuticals Inc. said Monday it received a Food and Drug Administration request for information on manufacturing and a risk mitigation plan for a potential once-weekly diabetes treatment.


 

Related items

US restricts, EU bans controversial diabetes pill
European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack...

Diet Treatment, Already in Use, to Get F.D.A. Review
The Food and Drug Administration will review a new diet pill consisting of a combination of two pills people are using in California to lose weight.

Notable 52-Week Highs and Lows of the Day 02/02:...
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High:Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) high of $17.60....

Samsung SCX-4200 3-in-1 True Multifunction Printer
The SCX-4200 Digital Productivity Center is a low cost black and white laser printer, delivering 3 in 1 true multifunction performance with professional laser output.Keep your valuable real...

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com